Neuropeptide Expression in Neurons for Behavioral State Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to effectively mimic the behavioral effects of neuropeptides, as direct administration of neuropeptides across the blood-brain barrier is challenging, and small molecule neuropeptide receptor agonists and antagonists fail to replicate the complex behavioral states controlled by these peptides.
Innovation Solution
A method involving the expression of neuropeptides in neurons, combined with the activation of these neurons using conditional receptors, such as hM3DREADD or optogenetic channels, to induce changes in neuronal polarity and behavior, using vectors like AAV to deliver nucleic acids encoding neuropeptides and receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct administration of neuropeptides is used, then the neuropeptide can reach target cells, but the blood-brain barrier prevents effective delivery to central nervous system neurons
Solution Approach 1:
The patent uses viral vectors (AAV, lentivirus) as intermediary carriers to deliver neuropeptide-encoding nucleic acids across the blood-brain barrier. These vectors transduce neurons and enable endogenous neuropeptide production, bypassing the barrier that blocks direct neuropeptide administration.
Solution Approach 2:
The patent replaces the mechanical/chemical approach of direct neuropeptide injection with a genetic approach using viral vectors and promoters. This substitution allows neuropeptide genes to be delivered and expressed within neurons, overcoming the physical barrier of the blood-brain barrier.
2Reliability
If small molecule neuropeptide receptor agonists and antagonists are used, then receptor binding can be achieved, but the complex behavioral states controlled by neuropeptides cannot be replicated
Solution Approach 1:
The patent copies the natural neuropeptide system by delivering the actual neuropeptide-encoding genes to neurons, enabling endogenous production and release. This replicates the complete physiological pathway including synthesis, storage, and regulated release, rather than merely copying receptor binding effects with small molecules.
Solution Approach 2:
The patent performs preliminary action by establishing transgenic expression of neuropeptides in specific neuron populations before behavioral manipulation. This allows subsequent physiological release mechanisms to naturally produce the desired behavioral effects, rather than attempting to directly induce complex behaviors.
3Reliability
If neuropeptides are administered directly, then the substance can be delivered, but the complex release patterns and timing of endogenous neuropeptides cannot be replicated
Solution Approach 1:
The patent enables neurons to self-produce and self-regulate neuropeptide release through endogenous gene expression. The transduced neurons automatically synthesize, store, and release neuropeptides in response to physiological stimuli, replicating natural release patterns without external intervention.
Solution Approach 2:
The patent restores periodic and stimulus-dependent release patterns by re-establishing endogenous neuropeptide production. Neurons naturally release neuropeptides in periodic bursts or in response to specific stimuli, replicating the temporal dynamics that cannot be achieved with continuous or intermittent direct administration.
4Reliability
If viral vectors are used to deliver nucleic acids, then neuropeptide expression can be achieved in target neurons, but the complexity of vector design and administration increases
Solution Approach 1:
The patent uses universal viral vector platforms (AAV, lentivirus) that can deliver multiple different neuropeptide genes through standardized construction and administration protocols. These vectors serve multiple functions including gene delivery, expression regulation, and long-term stability across different experimental conditions.
Solution Approach 2:
The patent optimizes vector parameters such as promoter selection, capsid serotype, and transgene design to enhance delivery efficiency and expression levels. By adjusting these parameters, the system achieves reliable neuropeptide expression while managing the inherent complexity of viral vector systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach successfully mimics the behavioral effects of endogenous neuropeptides by promoting their release, addressing symptoms like social isolation stress, aggression, and depression by altering neuronal polarity and inducing action potentials.
Implementation Method 1
The method can comprise administering a second nucleic acid to the neuron in the subject, the second nucleic acid encoding an conditional receptor configured to alter the polarity of the neuron upon application of an agonist or stimulus
Implementation Method 2
wherein the conditional receptor comprises an optogenic channel such as channel rhodopsin and the agonist comprises electromagnetic radiation
Implementation Method 3
The altered polarity in the neuron activates the neuron. In some embodiments, the altered polarity induces an action potential by the neuron
Data Source
Figure 1A~1D
Figure 1E
Figure 1F~1J
AI summary
Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.